Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (1)
Type
(
1 selected
)
Type
Guidance (96)
Guidance programme
Guidance programme
Technology appraisal guidance (96)
Apply filters
Showing 1 to 96 of 96
cancer
Remove cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung
cancer
[ID6339]
Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal
cancer
after 1 to 3 previous treatments TS ID 11830
Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate
cancer
TS ID 11967
Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast
cancer
ID 6200
Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung
cancer
[ID3894]
Technology appraisal guidance
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck
cancer
[ID4052]
Technology appraisal guidance
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate
cancer
after 1 therapy [ID6203]
Technology appraisal guidance
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast
cancer
[ID6152]
Technology appraisal guidance
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial
cancer
TSID 10710
Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast
cancer
TS ID 11769
Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate
cancer
after 1 hormonal treatment [ID6387]
Technology appraisal guidance
Capivasertib with paclitaxel for untreated metastatic triple-negative breast
cancer
[ID6383]
Technology appraisal guidance
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate
cancer
TSID 12045
Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast
cancer
[ID6435]
Technology appraisal guidance
Datopotamab deruxtecan for treating advanced non-small-cell lung
cancer
after platinum-based chemotherapy TS ID 11840
Technology appraisal guidance
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate
cancer
TS ID 11933
Technology appraisal guidance
Dostarlimab with carboplatin and paclitaxel for untreated recurrent or advanced endometrial
cancer
with high microsatellite stability or mismatch repair proficiency ID6415
Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal
cancer
[ID6311]
Technology appraisal guidance
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial
cancer
with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]
Technology appraisal guidance
Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder
cancer
[ID6168]
Technology appraisal guidance
Durvalumab for treating limited-stage small-cell lung
cancer
after chemoradiation [ID5073]
Technology appraisal guidance
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction
cancer
[ID6374]
Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal
cancer
before and after surgery [ID6254]
Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder
cancer
after resection of papillary tumours in people previously untreated with BCG [ID 5080]
Technology appraisal guidance
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder
cancer
when cisplatin is unsuitable TS ID 11989
Technology appraisal guidance
Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung
cancer
(Review of TA662) [ID6404]
Technology appraisal guidance
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial
cancer
[ID3855]
Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung
cancer
after chemoradiation [ID 5097]
Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung
cancer
after chemoradiation [ID5097]
Technology appraisal guidance
Dusquetide for treating oral mucositis during chemoradiation for head and neck
cancer
[ID3830]
Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder
cancer
TS ID 10718
Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal
cancer
[ID6278]
Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast
cancer
[ID 5072]
Technology appraisal guidance
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast
cancer
TS ID 11990
Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung
cancer
after a tyrosine kinase inhibitor TS ID 11822
Technology appraisal guidance
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck
cancer
TS ID 10203
Technology appraisal guidance
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung
cancer
TS ID 11970
Technology appraisal guidance
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal
cancer
ID6442
Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate
cancer
TSID 12044
Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate
cancer
TS ID 10523
Technology appraisal guidance
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial
cancer
[ID6316]
Technology appraisal guidance
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung
cancer
after platinum-based chemotherapy with pembrolizumab [ID6345]
Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder
cancer
[ID6321]
Technology appraisal guidance
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell lung
cancer
after platinum-based chemoradiation [ID6223]
Technology appraisal guidance
Ovarian, fallopian tube, peritoneal
cancer
(platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]
Technology appraisal guidance
Palbociclib for treating high-risk early breast
cancer
after neoadjuvant chemotherapy [ID3846]
Technology appraisal guidance
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast
cancer
[ID6251]
Technology appraisal guidance
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder
cancer
TSID 12021
Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder
cancer
[ID6271]
Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical
cancer
TS ID 10690
Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder
cancer
TS ID 11953
Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung
cancer
ID 6399
Technology appraisal guidance
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal
cancer
TS ID 11852
Technology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial
cancer
after surgery with curative intent TS ID 11808
Technology appraisal guidance
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder
cancer
[ID6219]
Technology appraisal guidance
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast
cancer
[ID6285]
Technology appraisal guidance
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal
cancer
[ID3853]
Technology appraisal guidance
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate
cancer
TS ID 11810
Technology appraisal guidance
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction
cancer
TS ID 11861
Technology appraisal guidance
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast
cancer
[ID3993]
Technology appraisal guidance
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung
cancer
TS ID 11975
Technology appraisal guidance
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung
cancer
[ID6149]
Technology appraisal guidance
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung
cancer
[ID6365]
Technology appraisal guidance
Plinabulin with docetaxel for previously treated advanced non-small-cell lung
cancer
[ID3895]
Technology appraisal guidance
Prostate
cancer
(hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]
Technology appraisal guidance
Repotrectinib for treating ROS1-positive advanced non-small-cell lung
cancer
TS ID 11851
Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung
cancer
ID 6436
Technology appraisal guidance
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction
cancer
after 2 or more therapies [ID3819]
Technology appraisal guidance
Rucaparib for treating hormone-relapsed metastatic prostate
cancer
with homologous recombination deficiency after 1 therapy TS ID 10764
Technology appraisal guidance
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal
cancer
after 1 therapy TS ID 10763
Technology appraisal guidance
Sacituzumab govitecan for treating unresectable metastatic urothelial
cancer
[ID6150]
Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast
cancer
ID6433
Technology appraisal guidance
Selpercatinib for treating advanced thyroid
cancer
with RET alterations (MA review of TA742) [ID6288]
Technology appraisal guidance
Serplulimab with chemotherapy for untreated extensive-stage small-cell lung
cancer
[ID6346]
Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate
cancer
with a homologous recombination repair mutation TSID 12009
Technology appraisal guidance
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung
cancer
TS ID 11951
Technology appraisal guidance
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell
cancer
after chemoradiotherapy [ID6267]
Technology appraisal guidance
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung
cancer
after at least 2 cycles of platinum-based chemoradiation TS ID 11841
Technology appraisal guidance
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung
cancer
[ID5122]
Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell
cancer
[ID 5077]
Technology appraisal guidance
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell
cancer
[ID5113]
Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal
cancer
[ID6304]
Technology appraisal guidance
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction
cancer
[ID6157]
Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung
cancer
TS ID 10693
Technology appraisal guidance
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell
cancer
without previous systemic chemotherapy [ID6414]
Technology appraisal guidance
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal
cancer
[ID6406]
Technology appraisal guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast
cancer
TS ID 11910
Technology appraisal guidance
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung
cancer
after 1 or more therapies [ID3934]
Technology appraisal guidance
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast
cancer
after 2 or more endocrine treatments [ID6226]
Technology appraisal guidance
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast
cancer
after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]
Technology appraisal guidance
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast
cancer
after induction chemotherapy [ID6402]
Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast
cancer
after a taxane, trastuzumab or both together TS ID 11781
Technology appraisal guidance
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung
cancer
TS ID 11950
Technology appraisal guidance
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck
cancer
[ID6199]
Technology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract
cancer
after 1 or more systemic treatments TS ID 11952
Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic
cancer
TSID 12040
Technology appraisal guidance
Current page
1
Page
1
of
1
Results per page
10
25
50
All
Back to top